Posted: September 1, 2009

Henderson Morley selects NanoSight Instrumentation for Rapid Virus Titre Assessment

(Nanowerk News) NanoSight, manufacturers of unique nanoparticle characterization technology, announce that UK biotechnology company, Henderson Morley plc, is using nanoparticle tracking analysis (NTA) to quantify virus particle number for batch to batch control.
Henderson Morley is developing an exciting pipeline of anti-viral drugs and vaccines and biological products to fight a wide range of diseases in humans and animals. Their lead vaccine technology platform uses PREPS and L-particles which are virus-like particles derived from Human Herpes Virus 1 (HHV-1). These particles have the same size as herpes viruses, but do not contain viral DNA and are therefore sterile. Conventional viral quantification relies on the infectious yield of viruses but as these particles do not replicate, an alternate quantification technique had to be found.
Dr Chris Hartley, Principal Scientist at Henderson Morley
Dr Chris Hartley, Principal Scientist at Henderson Morley.
Previously the only way to quantify particle number relied on less accurate protein concentration measurements. The company had also used costly and time consuming electron microscopy through a local university, and although this gave good results, it was not practical for batch to batch quantification of the L and PREPS particles.
Several benefits have been produced since the purchase the NanoSight system. Henderson Morley’s Principal Scientist, Dr Chris Hartley, has been impressed with the speed and ease of use. “The reproducibility of results providing both particle size and particle counts in real time has been excellent. Also negligible on-going and running costs have meant that the NanoSight instrument is proving to be a very cost effective solution.”
NanoSight’s Head of Applications Science, Andrew Malloy, adds “It is clear that we have a solution to a widespread problem, that of assessing viral titre. The results we are delivering for a range of users in viral vaccine production are contributing directly to improving the yield and stability of their products throughout the production process. We are delighted that Henderson Morley were so quick to recognise the value these analyses can provide.”
To learn more about viruses and their characterization using NTA, please visit Register for the latest issue of NanoTrail, the company’s eNewsletter.
About NanoSight
NanoSight Ltd, of Salisbury, UK, is the world leading provider of instruments for the optical detection and real time analysis of sub-micron particles. The Company supplies unique instruments for nanoparticle analysis in the sub-micron region that have specific application in rapid assessment of viral titre. These instruments produce more accurate concentration results than plaque assay, and deliver them within minutes rather than overnight. Additionally they deliver a unique view of viral particles which validates the reported titre and provides assessment of any agglomeration. Founded in 2004, the company currently has approaching 200 systems in service worldwide, having begun commercial sales in 2006.
The Company has a growing base of users worldwide, including GlaxoSmithKline, Intervet, MedImmune, Merial, Novartis, Solvay and many universities.
Source: NanoSight (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: